Working… Menu
Trial record 1 of 1 for:    Brain Metastases in Norway
Previous Study | Return to List | Next Study

Brain Metastases in Norway - A Prospective Cohort Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03346655
Recruitment Status : Recruiting
First Posted : November 17, 2017
Last Update Posted : February 25, 2021
Norwegian Cancer Society
South-Eastern Norway Regional Health Authority
Information provided by (Responsible Party):
Olav Erich Yri, Oslo University Hospital

Brief Summary:

The overall aim and primary outcome of this study will be a descriptive analysis of the current treatment practice of BM in Norway. Specifically, it may give answers to the following research questions:

  • What is the true incidence of BM in Norway?
  • How are patients with BM treated at present?
  • Do treatments differ between hospitals?
  • How do treatments impact quality of life of the patients?
  • Which factors (treatment, tumor and host variables) can explain disease control, survival, symptom relief, and general functions?
  • How can BM staging be improved?

Condition or disease
Brain Metastases

Layout table for study information
Study Type : Observational [Patient Registry]
Estimated Enrollment : 3000 participants
Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration: 12 Months
Official Title: Brain Metastases in Norway - Improved Classification and Treatment. A Prospective Cohort Study
Actual Study Start Date : January 1, 2018
Estimated Primary Completion Date : January 1, 2022
Estimated Study Completion Date : January 1, 2023

Primary Outcome Measures :
  1. Overall survival after diagnosis of brain metastases [ Time Frame: Time from diagnosis of brain metastases till death of any cause, assessed up to 12 months ]
    Calculation of the overall survival times for each patient enrolled

Secondary Outcome Measures :
  1. Treatment offered to patients diagnosed with brain metastases [ Time Frame: 3 years ]
    Description of treatment offered

  2. Changes in patient reported symptoms and quality of life items through EORTC questionnaire QLQ PAL15 and submodule BN20 [ Time Frame: Monthly up to 12 months after inclusion ]
    Description of changes in patient reported outcomes through standardized questionnaires.European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for Cancer Patients receiving palliative care (EORTC QLQ-C15-PAL), covers items such as pain, physical and emotional functioning. The QLQ-BN20 contains questions on 7 single-item symptom scales (headaches, seizures, drowsiness, hair loss, itchy skin, leg weakness, and bladder control), and 4 multi-item scales (future uncertainty, visual disorder, motor dysfunction, and communication deficit). Patient's scores are translated into a scale from 1-100. A change of 10 points in one item is considered clinically significant.

Biospecimen Retention:   Samples With DNA

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients With previously or newly diagnosed cancer With radiologically proven brain metastases

Inclusion Criteria:

  • Verified cancer diagnosis of solid tumors (based on radiological, histological/cytological or operative evidence).
  • Brain metastases verified by computer tomography (CT), contrast-enhanced magnetic resonance imaging (MRI), or surgical biopsies
  • Age ≥ 18 years
  • Able to comply with study procedures
  • Able to provide written informed consent after information in Norwegian

Exclusion Criteria:

  • Primary brain tumors
  • Primary hematological malignancies (lymphomas, leukemias)
  • Previous diagnosis and/or treatment of BM
  • Unable to produce written informed consent after information in Norwegian

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03346655

Layout table for location contacts
Contact: Stein Kaasa, Professor +47 22 93 40 00
Contact: Marianne Jensen Hjermstad, Professor +47 23 02 68 28

Layout table for location information
Oslo University Hospital Recruiting
Oslo, Norway
Contact: Olav E Yri, MD, PhD    +47 22 93 40 00   
Contact: Marianne Jensen Hjermstad, Professor    +47 23 02 68 28   
Sponsors and Collaborators
Oslo University Hospital
Norwegian Cancer Society
South-Eastern Norway Regional Health Authority
Layout table for investigator information
Principal Investigator: Olav E Yri, MD Post-doc
Additional Information:

Layout table for additonal information
Responsible Party: Olav Erich Yri, MD, PhD, Postdoctoral research fellow, Oslo University Hospital Identifier: NCT03346655    
Other Study ID Numbers: 2017/1358
First Posted: November 17, 2017    Key Record Dates
Last Update Posted: February 25, 2021
Last Verified: February 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Olav Erich Yri, Oslo University Hospital:
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasm Metastasis
Brain Neoplasms
Brain Diseases
Neoplastic Processes
Pathologic Processes
Central Nervous System Neoplasms
Nervous System Neoplasms
Neoplasms by Site
Central Nervous System Diseases
Nervous System Diseases